# Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

> **NCT04631757** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab + SOX + Radiotherapy

## Key facts

- **NCT ID:** NCT04631757
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-15
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2020-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04631757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04631757, "Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04631757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*